A
36.88
0.93 (2.59%)
| Previous Close | 35.95 |
| Open | 37.44 |
| Volume | 3,693,151 |
| Avg. Volume (3M) | 1,831,243 |
| Market Cap | 4,444,777,984 |
| Price / Sales | 554.67 |
| Price / Book | 5.02 |
| 52 Weeks Range | |
| Earnings Date | 8 Aug 2025 |
| Operating Margin (TTM) | -8,360.90% |
| Diluted EPS (TTM) | -3.00 |
| Quarterly Revenue Growth (YOY) | -55.60% |
| Total Debt/Equity (MRQ) | 0.45% |
| Current Ratio (MRQ) | 16.91 |
| Operating Cash Flow (TTM) | -355.32 M |
| Levered Free Cash Flow (TTM) | -245.73 M |
| Return on Assets (TTM) | -22.47% |
| Return on Equity (TTM) | -34.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Avidity Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.90 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.17% |
| % Held by Institutions | 112.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 96.00 (Cantor Fitzgerald, 160.30%) | Buy |
| Median | 65.00 (76.25%) | |
| Low | 54.00 (B of A Securities, 46.42%) | Buy |
| Average | 68.00 (84.38%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 36.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 08 Aug 2025 | 62.00 (68.11%) | Buy | 46.29 |
| 10 Jun 2025 | 59.00 (59.98%) | Buy | 33.62 | |
| Chardan Capital | 08 Aug 2025 | 75.00 (103.36%) | Buy | 46.29 |
| 09 Jun 2025 | 75.00 (103.36%) | Buy | 32.66 | |
| Wells Fargo | 08 Aug 2025 | 75.00 (103.36%) | Buy | 46.29 |
| Goldman Sachs | 10 Jul 2025 | 55.00 (49.13%) | Buy | 31.47 |
| Cantor Fitzgerald | 27 Jun 2025 | 96.00 (160.30%) | Buy | 29.03 |
| Wolfe Research | 17 Jun 2025 | 55.00 (49.13%) | Buy | 29.36 |
| Raymond James | 11 Jun 2025 | 65.00 (76.25%) | Buy | 32.01 |
| Citigroup | 10 Jun 2025 | 75.00 (103.36%) | Buy | 33.62 |
| B of A Securities | 09 Jun 2025 | 54.00 (46.42%) | Buy | 32.66 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HUGHES STEVEN GEORGE | - | 46.35 | -2,208 | -102,341 |
| Aggregate Net Quantity | -2,208 | |||
| Aggregate Net Value ($) | -102,341 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 46.35 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HUGHES STEVEN GEORGE | Officer | 22 Aug 2025 | Automatic sell (-) | 2,208 | 46.35 | 102,341 |
| HUGHES STEVEN GEORGE | Officer | 22 Aug 2025 | Option execute | 2,208 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |